Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGWP.L Regulatory News (GWP)

  • There is currently no data for GWP

Director/PDMR Shareholding

30 Mar 2012 13:57

RNS Number : 4932A
GW Pharmaceuticals PLC
30 March 2012
 



 

GW Pharmaceuticals PLC Director/PDMR Shareholding

GW Pharmaceuticals PLC

30 March 2012

GW Pharmaceuticals PLC

GW Pharmaceuticals PLC ("GW Pharmaceuticals" or the "Company")

NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS

Porton Down, UK, 30th March 2012: GW Pharmaceuticals (AIM: GWP) hereby provides notification that the Company was notified on 29th March that Dr Geoffrey Guy, a Director and Executive Chairman of the Company, had completed the following series of transactions in the ordinary 0.1 pence shares of GW Pharmaceuticals plc.

On 26th March 2012, Dr Guy transferred 9,780 shares to his personal pension scheme. This transaction, representing less than 0.1% of the Company's current issued share capital, was completed when the middle market price was 90 pence per share.

On 27th March 2012, Dr Guy gifted 165,000 shares to a family member. This transaction, representing 0.12% of the Company's current issued share capital, was completed when the middle market price was 88 pence per share.

On 28th March 2012, Dr Guy gifted 200,000 shares to charity. This transaction, representing 0.15% of the Company's current issued share capital, was completed when the middle market price was 86.25 pence per share.

Following these transactions Dr Guy retains a beneficial interest in 17,187,654 GW Pharmaceuticals plc ordinary shares of 0.1 pence each, representing 12.9% of the Company's current issued share capital.

The total number of shares outstanding in the Company is 133,147,354 ordinary shares of 0.1 pence each.

Enquiries:

GW Pharmaceuticals PLC Tel: +44 (0)1980 557 000

Adam George, Company Secretary

Peel Hunt LLP (Nominated Adviser) Tel: +44 (0)207 418 8900

James Steel/Vijay Barathan

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSLLFEFVEIIVIF
Date   Source Headline
27th Jan 20157:01 amRNSNotice of Results
9th Jan 20154:24 pmRNSBlock Listing Application
8th Jan 201512:00 pmRNSUpdate on Epidiolex Program
8th Jan 201512:00 pmRNSResults in Sativex Phase 3 Cancer Pain Trial
22nd Dec 20147:00 amRNSGW Added to NASDAQ Biotechnology Index
17th Dec 20146:16 pmRNSPublication of UK Annual Report and Accounts
17th Dec 20144:49 pmRNSDirector/PDMR Shareholding
3rd Dec 20148:22 amRNSHolding(s) in Company
2nd Dec 201412:00 pmRNSFinal Results
26th Nov 20147:00 amRNSGW Presents at Piper Jaffray Healthcare Conference
24th Nov 20147:00 amRNSNotice of Results
17th Nov 20143:00 pmRNSPresenting at Jefferies 2014 Healthcare Conference
30th Oct 20147:00 amRNSPhase 2/3 Trial of Epidiolex in Dravet Syndrome
22nd Oct 20147:00 amRNSEpidiolex Orphan Designation from EMA
14th Oct 201412:00 pmRNSResults of Phase 2a Ulcerative Colitis Trial
14th Oct 201412:00 pmRNSNew Physician Reports of Epidiolex Treatment
7th Oct 20149:45 amRNSAdditional Listing
29th Sep 20141:00 pmRNSGW Research and Development Day Details
24th Sep 20147:00 amRNSPresenting at Leerink Rare Disease Roundtable 2014
29th Aug 201412:20 pmRNSDirector/PDMR Shareholding
28th Aug 20147:00 amRNSPresenting at Upcoming Investor Conferences
18th Aug 201411:19 amRNSBlocklisting Interim Review
12th Aug 20144:32 pmRNSGrant of Options
6th Aug 20147:00 amRNSThird Quarter Financial Results
30th Jul 20147:00 amRNSNotice of Results
8th Jul 201410:18 amRNSHolding(s) in Company
30th Jun 20145:15 pmRNSHolding(s) in Company
30th Jun 20145:12 pmRNSHolding(s) in Company
30th Jun 20142:11 pmRNSHolding(s) in Company
25th Jun 20144:16 pmRNSClosing of U.S. Public Offering of ADSs on NASDAQ
24th Jun 20149:18 amRNSExercise of Underwriters' Option to Purchase ADSs
19th Jun 20147:00 amRNSPricing of U.S. Public Offering of ADSs
18th Jun 20147:00 amRNSProposed Public Offering of ADSs
17th Jun 201412:00 pmRNSEpidiolex IND Data
9th Jun 201412:34 pmRNSBlock Listing Application
6th Jun 20147:00 amRNSEpidiolex Fast Track Designation - Dravet Syndrome
29th May 20143:11 pmRNSHolding(s) in Company
8th May 20145:00 pmRNSPresenting at BAML 2014 Health Care Conference
7th May 20147:02 amRNSHalf Yearly Report
7th May 20147:00 amRNSIND for Epidiolex Ph 2/3 Trial in Dravet Syndrome
6th May 20145:54 pmRNSHolding(s) in Company
6th May 20147:01 amRNSAppointment of VP, Clinical Science
29th Apr 20145:30 pmRNSNotice of Results
28th Apr 20141:46 pmRNSHolding(s) in Company
28th Apr 20147:00 amRNSSativex FDA Fast Track Designation in Cancer Pain
19th Mar 20143:24 pmRNSHolding(s) in Company
17th Mar 20147:00 amRNSUpdate on Cannabinoid Pipeline
11th Mar 20142:34 pmRNSAnnual General Meeting
28th Feb 20141:00 pmRNSFDA Orphan Drug Designation received for Epidiolex
27th Feb 20147:00 amRNSGW to Present at Cowen Health Care Conference

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.